P822 Genome-wide association study (GWAS) of a Maltese inflammatory bowel disease cohort. (25th January 2019)

• Record Type: Journal Article
• Authors: Schembri, J; Pace, N; Vella, S; Piscopo, N; Degenhardt, F; Franke, A; Ellul, P
• Is Part Of: Journal of Crohn's and colitis. Volume 13(2019)Supplement 1
• Page Start: S534
• Page End: S534
• Publication Date: 2019-01-25
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjy222.946
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: Whilst most of the early inflammatory bowel disease (IBD) genetic studies were performed on Caucasian subjects, it is now increasingly recognised that different genes might be involved in different populations, especially from different ethnic backgrounds. Prior research in Maltese IBD patients had in fact determined that prevalence of NOD2 polymorphisms was very low, in stark contrast to IBD patients from mainland Europe. Hence, the aim of this study was to genotypically characterise a discovery cohort consisting of Maltese IBD patients. Methods: We conducted a case–control genetic association study using a hypothesis-free approach. Genotyping was carried out on the Illumina Immunochip platform. Results: After strict quality control 93 ulcerative colitis (UC), 160 Crohn's (CD) patients and 188 healthy controls remained. Figure 1 demonstrates no significant population stratification with evidence of several disease associated loci. Separate analyses were carried out for CD and UC and these are reported in Tables 1 and 2, respectively. Disease association with CD were larger in number and strength, compared with UC. Furthermore, whilst some loci contributed to both types of IBD, most demonstrated preferential association with either CD or UC (Figure 2). Conclusions: This study is the first genotype-association study in the Maltese IBD population and despite the relatively small sample size and lack of a replication cohort we recruited approximately one fourth of the country's entire IBD population. RAD51B, CDH1, HLA-DPB2 and MS4A5 represented the most significant polymorphisms and whilst several loci in our cohort are amongst the 231 known IBD risk loci, several others have never been associated with IBD. The previously reported low-prevalence of NOD2 polymorphisms in Maltese patients has been confirmed in our cohort, further validating our findings and highlighting the importance of biomedical research in small populations and under-represented communities.